CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn's Disease.
Lukasz KwapiszDavid H BruiningAkitoshi InoueYong S LeePhillip K EdwardsDavid R HolmesRickey E CarterJenifer SiegelmanJoel G FletcherPublished in: Crohn's & colitis 360 (2022)
Most patients on vedolizumab for over 12 months demonstrated response or stable SB disease when using objective cross-sectional radiologic imaging criteria using CTE/MRE.
Keyphrases
- small bowel
- cross sectional
- end stage renal disease
- ejection fraction
- newly diagnosed
- ulcerative colitis
- chronic kidney disease
- computed tomography
- high resolution
- patients with inflammatory bowel disease
- peritoneal dialysis
- prognostic factors
- magnetic resonance
- magnetic resonance imaging
- patient reported outcomes
- mass spectrometry
- pet ct